Seeking Alpha

GlaxoSmithKline (GSK) has officially admitted that senior executives in China "appear to have...

GlaxoSmithKline (GSK) has officially admitted that senior executives in China "appear to have acted outside of our processes and controls which breaches Chinese law." The company intends to reform its Chinese operations and lower drug prices in the country. Britain's Serious Fraud Office is reportedly conducting a preliminary review and could impose its own sanctions, as could the U.S. Justice Department. CEO Andrew Witty is set to provide details about GSK's response to the scandal when it presents its quarterly results on Wednesday.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs